Table 2.

Cox proportional hazards analyses of the prognostic and predictive value of BRCA1-like status for RFS and OS.

	RFS				OS
Variable	No. events/no. patients	HRa	95% CI	P-value	No. events/no. patients	HRa	95% CI	P-value
DNA-based CNV pattern
BRCA1-like	19/61	1			17/61	1
Non-BRCA1-like	16/68	1.35	0.69–2.63	0.37	15/68	1.27	0.64–2.56	0.49
Non-BRCA1-like tumours
T + CEF	15/32	1			14/32	1
TX + CEX	4/29	0.23b	0.08–0.70	<0.01	3/29	0.19c	0.05–0.66	<0.01
BRCA1-like tumours
T + CEF	10/37	1			9/37	1
TX + CEX	6/31	0.66b	0.24–1.81	0.42	6/31	0.75c	0.27–2.11	0.59

RFS recurrence-free survival, OS overall survival, HR hazard ratio, CI confidence interval, CNV copy number variation, T + CEF 3 cycles of docetaxel 3-weekly, followed by 3 cycles of cyclophosphamide, epirubicin and fluorouracil, 3-weekly, TX + CEX 3 cycles of capecitabine plus docetaxel 3-weekly, followed by 3 cycles of cyclophosphamide, epirubicin and capecitabine, 3-weekly.

Interaction test between BRCA1-like status and chemotherapy regimen:

^aAll Cox proportional hazard analyses shown here were unadjusted for clinicopathologic variables. Similar results were obtained when adjusted for one covariate at the time (due to the relatively small number of events).

^bP = 0.17;

^cP = 0.09.